US20190321426A1 – October 24, 2019 – COMBINATION THERAPIES WITH CANNABIS PLANT EXTRACT

Please complete the required fields.




Inventors :

Ruth GALLILY

Owner :

TIKUN OLAM LTD

Application Number :

US16346901

Document Number :

US20190321426A1

Priority Date :

November 2, 2017

Filing Date :

November 2, 2017

Date of Grant/ Publication :

October 24, 2019

Class :

A61K36 / 185; A61K31 / 05; A61K31 / 352; A61K9 / 00; A61P25 / 00

Abstract

Provided are methods and formulations utilized in the methods which include cannabis plant extracts and copaxone

Claim(s)

52 . A method for reducing, inhibiting, attenuating or eliminating at least one side effect associated with injecting glatiramer acetate (GA) to a subject suffering from an injection site reaction caused by the administration of GA, said method comprises oral, transdermal or topical administering to the subject an effective amount of a composition comprising an extract of at least one cannabis plant simultaneously with, prior to or after injecting GA.;
53 . A method for reducing, inhibiting, attenuating or eliminating at least one effect of an injection site reaction associated with injecting glatiramer acetate (GA) in a subject suffering from an injection site reaction caused by the administration of GA, said method comprises administering to the subject simultaneously with, prior to or after injecting GA an effective amount of an oral, topical or transdermal composition comprising an extract of at least one cannabis plant.;
60 . A method for treating, preventing, ameliorating or delaying the onset of multiple sclerosis (MS) in a subject, said method comprising administering to the subject a combination therapy comprising co-administering of a therapeutically effective amount of glatiramer acetate (GA) and a therapeutically effective amount of an oral, topical or transdermal composition comprising an extract of at least one cannabis plant.;
66 . A method for treating, preventing, ameliorating or delaying the onset of multiple sclerosis or reducing the frequency of relapses in the relapsing-remitting multiple sclerosis (RRMS) in a subject suffering therefrom, or in a subject who is predicted to suffer from said disease, or who has been diagnosed to potentially develop the disease, said method comprising administrating to said subject a therapeutically effective amount of a composition comprising an extract of the cannabis plant designated herein as “Avidekel”.;
67 . A method for reducing, inhibiting, attenuating or eliminating at least one side effect associated with injecting glatiramer acetate (GA) to a subject, said method comprising administrating to the subject a therapeutically effective amount of a composition comprising an extract of the cannabis plant designated herein as “Avidekel”.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login